Over-representation of the G12S polymorphism of the SDHD gene in patients with MEN2A syndrome

OBJECTIVE: To evaluate whether germline variants of the succinate dehydrogenase genes might be phenotypic modifiers in patients with multiple endocrine neoplasia type 2. Mutations of genes encoding subunits of the succinate dehydrogenase are associated with hereditary paraganglioma/pheochromocytoma syndrome. Pheochromocytoma is one of the main manifestations of multiple endocrine neoplasia type 2 caused by germline mutation of the rearranged during transfection proto-oncogene. METHODS: Polymorphisms of the succinate dehydrogenase genes were analyzed in 77 rearranged during transfection mutation carriers, 47 patients with sporadic medullary thyroid cancer, 48 patients with sporadic Pheo, and 100 healthy individuals. Exons 10–16 of the rearranged during transfection proto-oncogene were analyzed by direct DNA sequencing, and all exons of the von Hippel-Lindau, succinate dehydrogenase B, and succinate dehydrogenase subunit D genes were tested by direct DNA sequencing and multiple ligation probe analysis. The G12S polymorphism of the succinate dehydrogenase subunit D gene was determined by restriction fragment length polymorphism. RESULTS: Of the 77 rearranged during transfection mutation carriers, 55 from 16 families had multiple endocrine neoplasia type 2A, three from three families had multiple endocrine neoplasia type 2B, and 19 from two families had familial medullary thyroid carcinoma. Eight of 55 (14.5%) patients with multiple endocrine neoplasia type 2A had this variant whereas it was absent in multiple endocrine neoplasia type 2B, familial medullary thyroid carcinoma, sporadic medullary thyroid carcinoma, and sporadic pheochromocytoma groups, and its prevalence in controls was 1% (p<0.002 multiple endocrine neoplasia type 2A versus controls). No associations between G12S and age of manifestation, incidence of pheochromocytoma or hyperparathyroidism, or level of serum calcitonin were observed. CONCLUSION: The high prevalence of the G12S variant in patients with multiple endocrine neoplasia type 2A raises questions about its role as a genetic modifier, but this proposal remains to be established.

[1]  C Eng,et al.  The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. , 1996, JAMA.

[2]  M. Taniwaki,et al.  Characterization of the human SDHD gene encoding the small subunit of cytochrome b (cybS) in mitochondrial succinate-ubiquinone oxidoreductase. , 1999, Biochimica et biophysica acta.

[3]  B. Ponder,et al.  Modulation of medullary thyroid carcinoma penetrance suggests the presence of modifier genes in a RET transgenic mouse model. , 2003, Cancer research.

[4]  G. NelsonWohllk,et al.  [G691S, L769L and S836S ret proto-oncogene polymorphisms are not associated with higher risk to sporadic medullary thyroid carcinoma in Chilean patients]. , 2005 .

[5]  Ulrich Müller,et al.  Mutations in SDHC cause autosomal dominant paraganglioma, type 3 , 2000, Nature Genetics.

[6]  J. Benítez,et al.  Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. , 2003, Cancer research.

[7]  S. Borrego,et al.  Specific polymorphisms in the RETproto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression , 1999, Journal of medical genetics.

[8]  Charis Eng,et al.  Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. , 2008, American journal of human genetics.

[9]  P. Devilee,et al.  Nearly all hereditary paragangliomas in The Netherlands are caused by two founder mutations in the SDHD gene , 2001, Genes, chromosomes & cancer.

[10]  G. Heinze,et al.  Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma? , 2005, The Journal of clinical endocrinology and metabolism.

[11]  B. Ponder,et al.  Polymorphisms in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia type 2A. , 2006, Cancer research.

[12]  A. Pereira,et al.  Evaluation of RET polymorphisms in a six‐generation family with G533C RET mutation: specific RET variants may modulate age at onset and clinical presentation , 2009, Clinical endocrinology.

[13]  M. Honavar,et al.  Germline succinate dehydrogenase subunit D mutation segregating with familial non-RET C cell hyperplasia. , 2003, The Journal of clinical endocrinology and metabolism.

[14]  A. Pinchera,et al.  RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. , 2004, The Journal of clinical endocrinology and metabolism.

[15]  B. Ponder,et al.  Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma. , 2005, The Journal of clinical endocrinology and metabolism.

[16]  B. Ponder,et al.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A , 1993, Nature.

[17]  B. Devlin,et al.  Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. , 2000, Science.

[18]  P. Igaz,et al.  Segregation of the V804L mutation and S836S polymorphism of exon 14 of the RET gene in an extended kindred with familial medullary thyroid cancer , 2003, Clinical genetics.

[19]  D. Neuberg,et al.  Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation , 1999, Oncogene.

[20]  B. Ponder,et al.  Succinate dehydrogenase D variants do not constitute a risk factor for developing C cell hyperplasia or sporadic medullary thyroid carcinoma. , 2005, The Journal of clinical endocrinology and metabolism.

[21]  M. Montani,et al.  No mutations but an increased frequency of SDHx polymorphisms in patients with sporadic and familial medullary thyroid carcinoma. , 2005, Endocrine-related cancer.

[22]  Steven P. Gygi,et al.  SDH5, a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in Paraganglioma , 2009, Science.

[23]  K. Rácz,et al.  Clinical and biochemical features of sporadic and hereditary phaeochromocytomas: an analysis of 41 cases investigated in a single endocrine centre , 2004, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[24]  Nelson Wohllk G,et al.  [G691S, L769L and S836S ret proto-oncogene polymorphisms are not associated with higher risk to sporadic medullary thyroid carcinoma in Chilean patients]. , 2005, Revista medica de Chile.

[25]  J. Benítez,et al.  G12S and H50R variations are polymorphisms in the SDHD gene , 2003, Genes, chromosomes & cancer.

[26]  M. Rothmund,et al.  Mutations and polymorphisms in the SDHB, SDHD, VHL, and RET genes in sporadic and familial pheochromocytomas , 2009, Endocrine.

[27]  J. Moisan,et al.  Germline‐sequence variants S836S and L769L in the RE arranged during Transfection (RET) proto‐oncogene are not associated with predisposition to sporadic medullary carcinoma in the French population , 2004, Clinical genetics.

[28]  L. Mulligan,et al.  Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. , 1994, Human molecular genetics.

[29]  P. Igaz,et al.  Germline VHL gene mutations in Hungarian families with von Hippel-Lindau disease and patients with apparently sporadic unilateral pheochromocytomas. , 2009, European journal of endocrinology.

[30]  S. Oishi,et al.  Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome). , 1995, Endocrine journal.

[31]  E S Husebye,et al.  Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. , 2001, American journal of human genetics.